ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company is headquartered in Yokneam Illit, Israel.
| Revenue (TTM) | $21.82M |
| Gross Profit (TTM) | $7.85M |
| EBITDA | $-22.98M |
| Operating Margin | -62.70% |
| Return on Equity | -225.60% |
| Return on Assets | -47.30% |
| Revenue/Share (TTM) | $12.04 |
| Book Value | $2.26 |
| Price-to-Book | 3.33 |
| Price-to-Sales (TTM) | 0.96 |
| EV/Revenue | 0.877 |
| EV/EBITDA | 1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 15.70% |
| Shares Outstanding | $2.83M |
| Float | $1.56M |
| % Insiders | 47.45% |
| % Institutions | 1.42% |
Volatility is currently expanding
Lifeward (LFWD) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to a loss of $6.96 per share a year ago.
Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support con tinued commercial execution HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its second quarter 2026 financial results on Friday, August 14, 2026. A press release will be issued and quarterly report will be filed with the SEC prior to 9:30 a.m. ET. The Company will not conduct a conference call.
Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward's strategy to broaden ReWalk access through capital-efficient channel partner model intended to accelerate growth, expand patient access and improve commercial scalability HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.
Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones
Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic disease
Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $5.52 per share a year ago.
Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery ™ biomed technology , with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in o perating expenses and cash utilization as company prepares to scale neurorehabilit ati on products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass.
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LFWD and any ticker you trade — then tracks every position and per-strategy win rate.
